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Introduction
Recently, the pharmaceutical industry is increasingly focusing in the use of perfusion mode. Nevertheless, the optimal perfusion rate
during biopharmaceutical perfusion production is dependent on cell metabolism which can be characterized by mathematical models.
This study provides insights into the predictive capacities of systematic and simple cell modeling approaches of metabolism, growth
and production of monoclonal antibodies (mAb) [1] to optimize medium composition and perfusion rate during CHO perfusion culture

We applied the metabolic steady state concept and used a segmented linear model to predict cell metabolism. The external metabolite
rates are expressed as a linear function of the specific growth rate with various breakpoints associated to metabolic shifts [1]. The
composition of the perfusion medium was optimized based on this model. This model was used as a controller to determine the daily
perfusion rate as a function of the experimental specific growth rate. Two 2 L perfusion cultures using alternative tangential flow (ATF)
were performed and analyzed.
Figure 1 Macroscopic metabolic model application to
perfusion production development

Conclusions
 Using the cell metabolism model structure and parameter values from Ben Yahia et al. [1], it was possible to predict metabolic rates of new perfusion cultures in 2 L scale.
 The model was used to determine the medium composition and to control online the daily perfusion rate.

Modeling approach: In Silico model

Application to Perfusion Productions

Metabolic model representation
𝑟𝒊 : 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑒 𝑜𝑓 𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒 𝑖
𝝁: 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑔𝑟𝑜𝑤𝑡ℎ 𝑟𝑎𝑡𝑒
𝒂𝒊 : 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑐𝑒𝑙𝑙 𝑦𝑖𝑒𝑙𝑑 𝑜𝑛 𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒 𝑖
𝑏𝑖 : 𝑛𝑜𝑛 𝑔𝑟𝑜𝑤𝑡ℎ − 𝑎𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑒𝑑 𝑐𝑜𝑚𝑠𝑢𝑚𝑝𝑡𝑖𝑜𝑛 𝑜𝑓 𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒 𝑖

VCD (*106 cells/mL)

𝒓𝒊 = 𝒂𝒊 ∗ 𝝁 + 𝒃𝒊

Experiment

Two perfusion productions were performed
using optimized perfusion media and
model-based perfusion rates. Data are
compared to equivalent fed-batch process.
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Time (Day)



Figure 3
Comparison of the experimental cell growth of 2 perfusion
processes with fed-batch process. For “perfusion 1” (red), three
VCD were targeted (20, 40 and 70 *106 cells/mL). For “perfusion
2” (green), two VCD were targeted (60 and 120 *106 cells/mL)




Figure 2 Methodology to predict cell metabolism

Model Calibration

Experiment

Viability (%)

Segmented regression is performed on ri as function of
growth rate. Segmented linear regression is a method of
regression in which the coefficients of the regression are
function of the intervals of the input variable. The model is
based on the steady state paradigm.

The segmented linear model was calibrated with
12*2L bioreactor runs (least-square minimization)
in Fed-Batch mode [1].

Time (Day)
Figure 4
Comparison of the experimental viability of 2 perfusion
processes with fed-batch process. For “perfusion 1” (red) and
“perfusion 2” (green), viability was maintained constant and
higher than 95% during all production whereas viability dropped
to 80% for fed-batch process.

12 bioreactors in fed-batch mode
(model calibration)

Material and Method
The calibrated metabolic model was used to optimize
perfusion media in order to keep all amino acid constant
with one single nutrient source.

Max VCD (*106 cells/mL)

Experiment

Perfusion rate was also adapted for each steady state
using calibrated model but also the experimental specific
growth rate as an input

Equipments
ATF (Alternate tangential filtration)
• Polyethersulfone fibers, 0.2 µM
• Back-flush
• 0.9 LPM
Culture volume: 1.3L
2 perfusion productions tested with different target
viable cell density (VCD) for 20 days.

Figure 5
Comparison of the experimental volumetric productivity normalized
to the highest volumetric productivity reached. Both perfusion
productions reached higher volumetric productivity than fed-batch
process. As expected, “perfusion 2” has the higher volumetric
productivity which can be related to the high VCD targeted (5 times
higher than fed-batch process).

Figure 6
Amino acid concentrations in the bioreactor during “perfusion 1” production. The
dashed green line represents when the model was used to calculate the theoretical
optimized perfusion rate. For most of the amino acids, the concentration in the
bioreactor remains constant after the model was applied. Those profiles support the
hypothesis that the model developed for fed-batch production can be applied to
perfusion production.

Summary
When traditional experience-based sequential process development is used, the time pressures of the biopharmaceutical

[1] Ben Yahia, B., Gourevitch, B., Malphettes, L., Heinzle, E., 2016. Segmented linear
modeling of CHO fed-batch culture and its application to large scale production. Biotechnol
Bioeng. 114(4): 785-797.

industry make it very difficult to fully optimize and understand processes prior to scale-up. Here we showed that applying
the model developed in fed-batch by Ben Yahia et al. enables the successful optimization of the perfusion medium
composition as well as the online determination of the perfusion rate in silico. Hence this novel in silico development
approach alleviates the need for labor intensive and time consuming wet experiments while significantly enhancing
performance, accelerating and reducing the costs of process development.

